PTC Therapeutics, Inc.
PTCT· Nasdaq
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2013 | Q2 2012 |
|---|---|---|
| Revenue | $6.85M | $7.59M |
| Net Income | -$14.59M | -$6.07M |
| EPS Diluted | -$5.51 | $48.29 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
PTC Therapeutics, Inc. · CIK 1070081 · Engraved from SEC EDGAR